<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>52</patient-age><report-id>PHFR2012GB006358</report-id><gender>male</gender><reactions><reaction>Lymphoma</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>OCTREOTIDE</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Hypoglycaemia</indication></indications><patient-age>52</patient-age><outcomes><outcome>Life Threatening</outcome></outcomes><country>United Kingdom</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053193_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134631</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHFR2012GB006358</safetyreportid>
		<primarysourcecountry>GB</primarysourcecountry>
		<occurcountry>GB</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-10</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>1</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-07</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-07</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb>GB-MHRA-EYC 00096049</authoritynumb>
		<duplicate>1</duplicate>
		<medicallyconfirm>1</medicallyconfirm>
		<reportduplicate>
			<duplicatesource>MHRA</duplicatesource>
			<duplicatenumb>GB-MHRA-EYC 00096049</duplicatenumb>
		</reportduplicate>
		<reportduplicate>
			<duplicatesource>MHRA</duplicatesource>
			<duplicatenumb>GB-MHRA-ADR 21937808</duplicatenumb>
		</reportduplicate>
		<primarysource>
			<reportertitle>Mr</reportertitle>
			<reportergivename>Mick</reportergivename>
			<reporterfamilyname>Foy</reporterfamilyname>
			<reporterstreet>15-2 Market Towers, 1 Nine Elms Lane, Market Towers</reporterstreet>
			<reportercity>London</reportercity>
			<reporterpostcode>SW8 5NQ</reporterpostcode>
			<reportercountry>GB</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>GB</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>AP</patientinitial>
			<patientgpmedicalrecordnumb>93012225</patientgpmedicalrecordnumb>
			<patientonsetage>52</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientweight>83.7</patientweight>
			<patientheight>163</patientheight>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Gastric bypass</patientepisodename>
				<patientmedicalcomment>The patient was taking octreotide for post gastric bypass hypoglycaemia.</patientmedicalcomment>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Lymphoma</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Lymphoma</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Lymphoma</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121117</reactionstartdate>
				<reactionfirsttime>416</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>OCTREOTIDE</medicinalproduct>
				<obtaindrugcountry>GB</obtaindrugcountry>
				<drugauthorizationnumb>19-667</drugauthorizationnumb>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>50</drugstructuredosagenumb>
				<drugstructuredosageunit code="004">micrograms</drugstructuredosageunit>
				<drugseparatedosagenumb>3</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>50 ug, TID</drugdosagetext>
				<drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypoglycaemia</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-09-28</drugstartdate>
				<drugstartperiod>416</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>OCTREOTIDE ACETATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Lymphoma</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Lymphoma</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHFR2012GB006358, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report from a <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>via health authority (MHRA) received on 07 Dec 2012. This report refers to a 52-year old male patient (93012225). On 28 Sep 2011, the patient received <Semaphore x="941733" class="Medicine" value="Octreotide" score="0.93" ID="273660">octreotide </Semaphore>(<Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer </Semaphore>unknown) at a dose of 50 mcg, once a day, SC, dose for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>for post <Semaphore x="2586114" class="AnatomicStructure" value="Stomach" score="1.00" ID="C12391">gastric </Semaphore><Semaphore x="1653643" class="Procedure" value="Bypass" score="1.00" ID="C15723">bypass </Semaphore><Semaphore x="3021343" class="MedDRA LLT" value="Hypoglycaemia" score="1.00" ID="10020993">hypoglycaemia</Semaphore>. On 17 Nov 2012, the patient developed <Semaphore x="2141674" class="Disease or Finding" value="Lymphoma" score="1.00" ID="C3208">lymphoma </Semaphore>(unknown type) while on <Semaphore x="941733" class="Medicine" value="Octreotide" score="0.93" ID="273660">octreotide</Semaphore>. The event was considered as serious (life threatening). The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event was not recovered. <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">Treatment </Semaphore>with <Semaphore x="941733" class="Medicine" value="Octreotide" score="0.93" ID="273660">octreotide </Semaphore>was <Semaphore x="1409602" class="Procedure" value="About What Time is it" score="1.00" ID="C110931">unchanged</Semaphore>. The causality of the event was probably unrelated to <Semaphore x="941733" class="Medicine" value="Octreotide" score="0.93" ID="273660">octreotide</Semaphore>.</narrativeincludeclinical>
				<sendercomment>limited information precludes a meaningful medical assessment.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>